This book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challe… Más…
This book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from its application in daily practice. The book is divided into 4 parts. The first part begins with the current technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. The second part deals with the use proteomics in cell signaling. At the present, the pharmaceutical and biotechnology industries have many potentially useful small molecule inhibitors of many pathways important in cancer that have yet to be taken to clinical trials. Understanding protein-protein interaction and posttranslational modifications through proteomics will likely make it much more feasible to do effective clinical trials of these small molecules alone and in combinations to overcome drug resistance and improve patient care. The third part of the book moves from signaling to actual clinical applications of proteomics in cancer therapy. Case studies in may tumor types are provided to show the feasibility of generating the critical information needed to individualization of therapy in cancer patients. The final part of the book provides in depth information on annotating the human proteome and the role of Food and Drug Administration (FDA) in regulating the use of proteomics in cancer therapy. To functionally annotate the human proteome, the Swiss Institute for Bioinformatics (SIB) and the European Bioinformatics Institute (EBI) initiated a major effort to distribute to the scientific community highly integrated information on human protein sequences. This initiative, which is called the Human Proteomics Initiative (HPI) aims to provide for each known human protein a wealth of information that include the description of its function, domain and protein family classification, subcellular location, posttranslational modifications, variants and similarities to other proteins. Integration of bioinformatics into clinical application of proteomics in cancer therapy is outlined as well as regulations and policy of commercial application of proteomics in patient care. Books > Biomedicine Soft cover, Springer Shop<
Springer.com
new in stock. Gastos de envío:zzgl. Versandkosten. (EUR 0.00) Details...
(*) Libro agotado significa que este título no está disponible por el momento en alguna de las plataformas asociadas que buscamos.
Paperback, [PU: Humana Press Inc.], It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in canc… Más…
Paperback, [PU: Humana Press Inc.], It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in cancer therapy, and looks at the role of the FDA in regulating the use of proteomics., Oncology<
BookDepository.com
Gastos de envío:Versandkostenfrei. (EUR 0.00) Details...
(*) Libro agotado significa que este título no está disponible por el momento en alguna de las plataformas asociadas que buscamos.
This book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challe… Más…
This book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from its application in daily practice. The book is divided into 4 parts. The first part begins with the current technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. The second part deals with the use proteomics in cell signaling. At the present, the pharmaceutical and biotechnology industries have many potentially useful small molecule inhibitors of many pathways important in cancer that have yet to be taken to clinical trials. Understanding protein-protein interaction and posttranslational modifications through proteomics will likely make it much more feasible to do effective clinical trials of these small molecules alone and in combinations to overcome drug resistance and improve patient care. The third part of the book moves from signaling to actual clinical applications of proteomics in cancer therapy. Case studies in may tumor types are provided to show the feasibility of generating the critical information needed to individualization of therapy in cancer patients. The final part of the book provides in depth information on annotating the human proteome and the role of Food and Drug Administration (FDA) in regulating the use of proteomics in cancer therapy. To functionally annotate the human proteome, the Swiss Institute for Bioinformatics (SIB) and the European Bioinformatics Institute (EBI) initiated a major effort to distribute to the scientific community highly integrated information on human protein sequences. This initiative, which is called the Human Proteomics Initiative (HPI) aims to provide for each known human protein a wealth of information that include the description of its function, domain and protein family classification, subcellular location, posttranslational modifications, variants and similarities to other proteins. Integration of bioinformatics into clinical application of proteomics in cancer therapy is outlined as well as regulations and policy of commercial application of proteomics in patient care. Books > Biomedicine Soft cover, Springer Shop<
new in stock. Gastos de envío:zzgl. Versandkosten. (EUR 0.00)
Paperback, [PU: Humana Press Inc.], It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in canc… Más…
Paperback, [PU: Humana Press Inc.], It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in cancer therapy, and looks at the role of the FDA in regulating the use of proteomics., Oncology<
1Dado que algunas plataformas no nos comunican las condiciones de envío y éstas pueden depender del país de entrega, del precio de compra, del peso y tamaño del artículo, de una posible membresía a la plataforma, de una entrega directa por parte de la plataforma o a través de un tercero (Marketplace), etc., es posible que los gastos de envío indicados por eurolibro/terralibro no concuerden con los de la plataforma ofertante.
This book covers current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from its application in daily practice. It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in cancer therapy, and looks at the role of the FDA in regulating the use of proteomics.
Detalles del libro - Cancer Proteomics: From Bench to Bedside
EAN (ISBN-13): 9781617378072 ISBN (ISBN-10): 1617378070 Tapa dura Tapa blanda Año de publicación: 2010 Editorial: SPRINGER VERLAG GMBH 276 Páginas Peso: 0,399 kg Idioma: eng/Englisch
Libro en la base de datos desde 2012-11-02T13:05:20-06:00 (Mexico City) Página de detalles modificada por última vez el 2021-09-19T10:24:38-05:00 (Mexico City) ISBN/EAN: 9781617378072
ISBN - escritura alterna: 1-61737-807-0, 978-1-61737-807-2 Mode alterno de escritura y términos de búsqueda relacionados: Autor del libro: daoud
Más, otros libros, que pueden ser muy parecidos a este: